THTX — Theratechnologies Income Statement
0.000.00%
Last trade - 00:00
- $58.46m
- $77.04m
- $81.76m
- 54
- 60
- 20
- 41
2019 November 30th | 2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 63.2 | 66.1 | 69.8 | 80.1 | 81.8 |
Cost of Revenue | |||||
Gross Profit | 37.1 | 38.2 | 46.6 | 53.8 | 62.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 71.7 | 84 | 95.1 | 120 | 95.8 |
Operating Profit | -8.51 | -18 | -25.2 | -39.6 | -14 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.5 | -22.7 | -31.7 | -46.8 | -23.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.5 | -22.7 | -31.7 | -47.2 | -24 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.5 | -22.7 | -31.7 | -47.2 | -24 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.5 | -22.7 | -31.7 | -47.2 | -24 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.65 | -1.21 | -1.37 | -1.99 | -0.825 |